AU2022308421A1 - Anti-tnfr2 antibody and uses thereof - Google Patents

Anti-tnfr2 antibody and uses thereof Download PDF

Info

Publication number
AU2022308421A1
AU2022308421A1 AU2022308421A AU2022308421A AU2022308421A1 AU 2022308421 A1 AU2022308421 A1 AU 2022308421A1 AU 2022308421 A AU2022308421 A AU 2022308421A AU 2022308421 A AU2022308421 A AU 2022308421A AU 2022308421 A1 AU2022308421 A1 AU 2022308421A1
Authority
AU
Australia
Prior art keywords
seq
sequence
tnfr2
antigen
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022308421A
Other languages
English (en)
Inventor
Francisco Adrian
Nicola Arturo Aldo BELTRAMINELLI
Matthieu DELINCE
Pascaline Mary
Andreas Raue
Liang SCHWEIZER
Jennifer Watkins
Shuo WEI
Qian Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hifibio Inc
Original Assignee
Hifibio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hifibio Inc filed Critical Hifibio Inc
Publication of AU2022308421A1 publication Critical patent/AU2022308421A1/en
Assigned to HIFIBIO, INC. reassignment HIFIBIO, INC. Request for Assignment Assignors: HIFIBIO (HK) LIMITED
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2022308421A 2021-07-07 2022-07-06 Anti-tnfr2 antibody and uses thereof Pending AU2022308421A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163219175P 2021-07-07 2021-07-07
US63/219,175 2021-07-07
PCT/IB2022/000409 WO2023281313A1 (en) 2021-07-07 2022-07-06 Anti-tnfr2 antibody and uses thereof

Publications (1)

Publication Number Publication Date
AU2022308421A1 true AU2022308421A1 (en) 2024-01-25

Family

ID=84800439

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022308421A Pending AU2022308421A1 (en) 2021-07-07 2022-07-06 Anti-tnfr2 antibody and uses thereof

Country Status (9)

Country Link
EP (1) EP4367140A4 (https=)
JP (1) JP2024527576A (https=)
KR (1) KR20240032985A (https=)
CN (1) CN117980336A (https=)
AR (1) AR126387A1 (https=)
AU (1) AU2022308421A1 (https=)
CA (1) CA3224693A1 (https=)
TW (1) TW202309096A (https=)
WO (1) WO2023281313A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3256751A1 (en) * 2022-05-26 2023-11-30 Pfizer Inc. Anti-TNFR2 antibodies and their methods of use
WO2024233258A1 (en) * 2023-05-05 2024-11-14 Cureimmune Therapeutics Inc. Anti-tnfr2 antibodies and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190135929A1 (en) * 2015-08-28 2019-05-09 The General Hospital Corporation Agonistic anti-tumor necrosis factor receptor 2 antibodies
EP3707163A4 (en) * 2017-11-09 2021-08-18 The General Hospital Corporation POLYPEPTIDES ANTAGONISTS OF THE TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY
EP3853252A1 (en) * 2018-09-18 2021-07-28 Merrimack Pharmaceuticals, Inc. Anti-tnfr2 antibodies and uses thereof
CA3131953A1 (en) * 2019-03-01 2020-09-10 Merrimack Pharmaceuticals, Inc. Anti-tnfr2 antibodies and uses thereof
WO2021023098A1 (zh) * 2019-08-02 2021-02-11 江苏先声药业有限公司 抗tnfr2抗体及其用途
CA3154643A1 (en) * 2019-09-17 2021-03-25 Apexigen, Inc. Anti-tnfr2 antibodies and methods of use
CN112480259B (zh) * 2021-02-05 2021-05-04 百奥赛图(北京)医药科技股份有限公司 抗tnfr2抗体及其用途

Also Published As

Publication number Publication date
CA3224693A1 (en) 2023-01-12
EP4367140A4 (en) 2025-06-18
AR126387A1 (es) 2023-10-11
WO2023281313A1 (en) 2023-01-12
TW202309096A (zh) 2023-03-01
EP4367140A1 (en) 2024-05-15
JP2024527576A (ja) 2024-07-25
CN117980336A (zh) 2024-05-03
KR20240032985A (ko) 2024-03-12

Similar Documents

Publication Publication Date Title
JP7775347B2 (ja) 癌治療におけるｆｇｆｒ２阻害剤単独または免疫刺激剤との組み合わせ
EP3283527B1 (en) Combination therapy for cancer
US20230416382A1 (en) Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
JP7719799B2 (ja) 抗ガレクチン－９抗体およびその使用
JP7801225B2 (ja) 抗ｔｎｆｒ２抗体及びその使用
AU2022308421A1 (en) Anti-tnfr2 antibody and uses thereof
US20240158517A1 (en) Anti-human cxcr5 antibody and uses thereof
WO2021129744A1 (en) Compositions and methods for treating autoimmune diseases and cancers by targeting igsf8
US12617860B2 (en) Anti-TNFR2 antibody and uses thereof
RU2840501C1 (ru) Анти-галектин-9 антитело и его применение
HK40092079A (zh) 抗tnfr2抗体和其用途

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: HIFIBIO, INC.

Free format text: FORMER APPLICANT(S): HIFIBIO (HK) LIMITED